Pharmaceutical giants Pfizer and Moderna have begun mandated studies into the links between their vaccines and soaring levels of heart damage in recipients.
As part of its approval process for the shots, the FDA has mandated that both Big Pharma companies must conduct clinical trials on vaccine-related myocarditis.
Myocarditis is inflammation of the heart muscle (myocardium), according to Mayo Clinic.
The inflammation damages the heart by reducing its ability to pump blood.
Severe myocarditis weakens the heart so that the rest of the body doesn’t get enough blood.
Clots can form in the heart, leading to a stroke or heart attack.
Cases of myocarditis have been skyrocketing in recent months following the widespread rollout of Covid vaccines, leading many to believe they are related.
And while Pfizer and Moderna’s new trials closely investigating vaccine myocarditis are underway, the news is barely being reported by the corporate media.
Only a handful of media outlets have reported on the new trials.
As NBC reports, “Moderna has already launched two trials, the most recent in September.
“Pfizer confirmed that at least one of its trials, which will include up to 500 teens and young adults under age 21, is slated to begin in the next couple of months.”
As has been long-established, mRNA vaccines induce myocarditis at alarmingly high rates in young men.
A new study published in the Journal of the American College of Cardiology compares rates of myocarditis between the Pfizer and Moderna vaccine.
For men aged 18 to 29, the study finds a vaccine myocarditis rate of 1 in 3,636 following a second dose of the Moderna vaccine.
For Pfizer, the authors report a rate of 1 in 20,000 in the same age group—roughly equal to the rate for Moderna in men ages 30 to 39.
Although the clinical myocarditis rate has been quantified in several high-quality studies, many serious concerns remain unaddressed.
One major concern is subclinical myocarditis, which covers serious myocardial symptoms that occur post-vaccination but don’t formally qualify as myocarditis.
The FDA has ordered Pfizer and Moderna to conduct a “substudy to prospectively assess the incidence of subclinical myocarditis following administration of the second dose of [vaccine] in a subset of participants 5 through 15 years of age.”
Currently, the only data on subclinical myocarditis following mRNA vaccination comes from a small Thai study.
Despite only studying 301 participants, the analysis found an alarming signal of heart damage in 13 to 18-year-olds:
“Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments.
“Cardiovascular effects were found in 29.24% of patients, ranging from tachycardia, palpitation, and myopericarditis.”
More worryingly, 3 out of 301 children in the study developed myocarditis or suspected pericarditis.
Meanwhile, another four children had elevated cardiac markers and were labeled as subclinical myocarditis.
The discovery of such high numbers of vaccine injuries in such a small study group is raising concerns among medical experts.
As Philadelphia cardiologist Dr. Anish Koka noted in his analysis, “We should be clear that no one currently knows the long-term significance of the clinical or subclinical myocarditis that is being diagnosed here.”
Another major concern surrounding mRNA vaccination is the long-term outcomes of vaccine myocarditis.
Anecdotally, we know vaccine myocarditis typically results in a few days of hospitalization followed by four to six months of highly restricted physical activity.
Even then, it isn’t clear if a “full recovery” is made.
Earlier this year, a CDC analysis, showed one-third of vaccine myocarditis patients were not fully recovered at the three-month follow-up.
As Koka noted, the survey contained troubling cardiac imaging findings: “53% had an abnormal cardiac MRI” and “47% had evidence of scarring by cardiac MRI.”
Moderna and Pfizer’s current trials will shed light on the true number of young men who have suffered from cardiac damage following vaccination, either clinical or subclinical.
However, it will take several years for all the data to be released.
Until such data is revealed, accurate cost-benefit analyses cannot be made since the real risk of cardiac vaccine injury is unclear.
The existing figures are egregious enough, but the full extent of the harm committed by the biopharmaceutical industry in lockstep with federal governments remains to be discovered.